Advise patients and caregivers to inform their healthcare professionals of all concomitant medications, including prescription and non-prescription medicines, vitamins and minerals, natural supplements or alternative medicines.1
Acid reducing agents
Co-administration of LUMAKRAS™ with PPI (omeprazole) or an H2 receptor antagonist (famotidine) led to an ⭣ in sotorasib concentrations.
Avoid co-administration of PPIs and H2 receptor antagonists with LUMAKRAS™ since it may reduce the efficacy of sotorasib.
If treatment with an acid-reducing agent cannot be avoided, take LUMAKRAS™ 4 hours before or 10 hours after administration of a local antacid.
Strong CYP3A4 inducers
Co-administration of LUMAKRAS™ with a strong CYP3A4 inducer (rifampin) led to a ⭣ in sotorasib concentrations.
Avoid co-administration of strong CYP3A4 inducers with LUMAKRAS™ since it may reduce the efficacy of sotorasib.
CYP3A4 substrates
LUMAKRAS™ is a moderate CYP3A4 inducer. LUMAKRAS™ ⭣ CYP3A4 substrates.
Avoid co-administration of LUMAKRAS™ and CYP3A4-sensitive substrates, for which minimal concentration changes may lead to therapeutic failures of the substrate.
If co-administration cannot be avoided, increase the CYP3A4 substrate dosage in accordance with approved product labelling.
P-gp substrates
Co-administration of LUMAKRAS™ with a P-gp substrate (digoxin) led to an ↑ in digoxin concentrations.
Avoid co-administration of LUMAKRAS™ and P-gp substrates, for which minimal concentration changes may lead to increased adverse reactions.
If co-administration cannot be avoided, decrease the P-gp substrate dosage in accordance with approved product labelling.
Adapted from the Product Monograph.1
Please see the Product Monograph for complete information on drug interactions.
PPI, proton pump inhibitor; P-gp, P-glycoprotein
